查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800914

囊性纤维化治疗市场报告（按药物类别、药物分子类型、给药途径、最终用户和地区划分）2025 年至 2033 年

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 118 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球囊性纤维化治疗市场规模达78亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到155亿美元，2025-2033年期间的复合年增长率（CAGR）为7.55%。囊性纤维化盛行率的上升、个人对基于遗传因素的个人化治疗方法的偏好日益增长，以及基因治疗领域最新进展的广泛应用，是推动市场成长的一些主要因素。

囊性纤维化疗法能够控制影响呼吸和消化系统的遗传性疾病的症状。它涵盖一系列药物，包括CFTR调节剂和基因疗法，提供个人化的治疗方案。它透过增强CFTR蛋白的功能来帮助纠正导致CF的潜在遗传缺陷。它透过控制症状和减缓疾病进展来提高生活品质。它可以增强肺功能，帮助CF患者更顺畅地呼吸，并减轻呼吸道症状。

个人对基于遗传因素的个人化治疗方法的偏好日益增长，这促进了市场的成长。此外，各国政府部门正在推出政策并资助囊性纤维化（CF）的研究和治疗开发，这为市场前景提供了良好的支撑。此外，孤儿药研发监管激励措施的持续增加，也鼓励製药公司投资囊性纤维化（CF）疗法。此外，製药公司、研究机构和医疗保健提供者之间日益加强的合作，正在加速新疗法的开发。此外，穿戴式装置和远距医疗等技术的广泛应用，也正在增强患者监测和治疗的有效性。

囊性纤维化治疗市场趋势/驱动因素：

CFTR调节剂的进展

CFTR调节剂药物的开发和持续改进是推动市场成长的主要因素之一。这些药物直接针对缺陷的CFTR蛋白，这是导致CF患者产生浓稠黏液并引发后续健康併发症的原因。此外，製药公司持续投入研发，以推出新一代CFTR调节剂，从而提供更有效率、更广泛的适用性。这些进展提供了更全面的解决方案，并改善了患者的整体健康。它们还有助于改善特定CF患者群体的黏液清除能力、减轻呼吸道症状并增强肺功能。

基因疗法的发展

基因疗法的发展是促进市场成长的另一个重要因素。这些创新疗法透过将功能性缺陷的CFTR基因拷贝引入受累细胞，从而促进CF的治癒或长期管理，有助于从根本上解决CF的病因。此外，基因疗法领域最新进展的利用率不断提高，例如Kaftrio和Trikafta等基因疗法已获准用于治疗CF症状，为市场带来了良好的前景。此外，基因疗法的发展也正在促进市场的成长。这些疗法有助于提供更有效、更有针对性的治疗，拓展治疗方案，并促进潜在治疗方法的研究。

盛行率上升和早期诊断

由于多种因素的影响，CF 盛行率不断上升，尤其是在千禧世代人群中，这推动了对治疗药物的需求。同时，诊断能力的提升也创造了积极的市场前景。此外，医疗保健系统透过新生儿筛检计画和基因检测，越来越擅长识别 CF 病例。此外，早期诊断使得患者能够在更年轻时开始治疗，从而显着影响病情进展并改善长期预后。此外，基因检测和新生儿筛检计画的不断进步，使得婴幼儿 CF 的诊断更加快速可靠。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球囊性纤维化治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 胰酵素补充剂
  • 黏液溶解剂
  • 支气管扩张剂
  • CFTR调节剂
  • 抗生素
  • 其他的

第七章：市场区隔：依药物分子类型

  • 小分子药物
  • 生物製剂

第八章：市场区隔：依行政途径

  • 口服药物
  • 吸入药物

第九章：市场区隔：依最终用户

  • 医院
  • 诊所
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
Product Code: SR112025A2117

The global cystic fibrosis therapeutics market size reached USD 7.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033. The rising prevalence of cystic fibrosis, increasing preferences of individuals for personalized treatment approaches based on genetic factors, and the widespread utilization of recent advancements in gene therapy are some of the major factors propelling the market growth.

Cystic fibrosis therapeutics enables management of the symptoms of a genetic disease affecting the respiratory and digestive systems. It encompasses a range of drugs, including CFTR modulators and gene therapy, offering tailored treatment options. It helps correct the underlying genetic defect responsible for CF by enhancing the function of the CFTR protein. It contributes to a better quality of life by managing symptoms and slowing disease progression. It can enhance lung function, helping individuals with CF breathe more easily and reducing respiratory symptoms.

Rising preferences of individuals for personalized treatment approaches based on genetic factors is strengthening the growth of the market. Apart from this, governing authorities of various countries are introducing policies and funding for CF research and treatment development, which is offering a favorable market outlook. Additionally, a continuous rise in regulatory incentives for orphan drug development is encouraging pharmaceutical companies to invest in CF therapeutics. Moreover, the rising collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new therapies. Furthermore, the widespread use of technology, such as wearable devices and telemedicine, is enhancing patient monitoring and treatment delivery.

Cystic Fibrosis Therapeutics Market Trends/Drivers:

Advancements in CFTR modulators

The development and continued improvement of CFTR modulator drugs represent one of the primary factors contributing to the market growth. These medications directly target the defective CFTR protein, which is responsible for the thick mucus production and subsequent health complications in individuals with CF. Apart from this, pharmaceutical companies are continuously investing in research and development (R&D) activities to introduce new generations of CFTR modulators that offer greater effectiveness and broader applicability. These advancements provide more comprehensive solutions and improve the overall well-being of individuals. They also support improved mucus clearance, reduced respiratory symptoms, and enhanced lung function in specific CF patient populations.

Development of gene-based therapies

The development of gene-based therapies is another major factor facilitating the market growth. These innovative treatments help address the root cause of CF by introducing functional copies of the defective CFTR gene into affected cells and facilitating a cure or long-term management of CF. Additionally, the rising utilization of recent advancements in gene therapy, such as the approval of gene-based treatments like Kaftrio and Trikafta for treating CF symptoms is offering a favorable market outlook. Apart from this, the evolution of gene-based therapies is strengthening the growth of the market. These therapies aid in providing more effective and targeted treatments, expanding treatment options, and fostering research into potential curative approaches.

Increasing prevalence and early diagnosis

The rising prevalence of CF, especially among the millennial population due to several factors, is driving the demand for therapeutics. Along with this, improved diagnostic capabilities are creating a positive market outlook. Additionally, healthcare systems are becoming more adept at identifying CF cases through newborn screening programs and genetic testing. Apart from this, early diagnosis allows for the initiation of treatment at a younger age, which can significantly impact disease progression and improve long-term outcomes. Furthermore, ongoing advancements in genetic testing and newborn screening programs are allowing for quicker and more reliable diagnosis of CF in infants and young children.

Cystic Fibrosis Therapeutics Industry Segmentation:

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

CFTR modulators hold the largest market share

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Small molecule drugs account for the majority of the market share

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Oral drugs dominate the market

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Hospitals dominate the market

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Europe leads the market, accounting for the largest cystic fibrosis therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share since the region has a well-developed healthcare infrastructure with widespread access to medical facilities and specialized CF centers. Additionally, Europe has a relatively high prevalence of CF. This increased prevalence drives research and development (R&D) efforts as well as market demand for CF therapeutics. Apart from this, Europe is home to some of the largest pharmaceutical companies in the world. These companies invest heavily in CF therapeutics, leading to the development of innovative treatments. Furthermore, the European Medicines Agency (EMA) provides a clear regulatory pathway for the approval of CF drugs. Moreover, many European governments allocate substantial funding to support CF research and treatment. This funding accelerates the development of new therapies and promotes market growth.

Competitive Landscape:

Companies are investing heavily in research and development (R&D) activities to discover new treatments and medications that target the underlying causes of cystic fibrosis. Additionally, they are working on therapies tailored to specific genetic mutations associated with cystic fibrosis. This ensures a more effective and targeted approach to treatment. Apart from this, many companies are forming partnerships with academic institutions, research organizations, and other pharma companies to accelerate drug development and bring new therapies to market more quickly. Furthermore, they are continuously conducting and investing in phase I, II, and III clinical trials to test the efficacy and safety of new cystic fibrosis therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Alaxia
  • Alcresta Therapeutics Inc.
  • Allergan
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.

Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cystic fibrosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global cystic fibrosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug molecule type?
  • Which is the most attractive drug molecule type in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the cystic fibrosis therapeutics market?
  • What is the competitive structure of the global cystic fibrosis therapeutics market?
  • Who are the key players/companies in the global cystic fibrosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2024
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2024
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million USD), 2025-2033
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players